Results 171 to 180 of about 398,363 (249)

Efficacy and safety of drug combinations for chronic pelvic pain: a systematic review. [PDF]

Pain Rep
Mohiuddin M, Park R, Wesselmann U, Pukall C, Jarvi K, Nickel JC, Doiron RC, Halliday S, Gilron I.   +8 more
europepmc   +1 more source

Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling

FEBS Open Bio, EarlyView.
Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero, Maria Kopsida, Nathalie Arendt, Hans Lennernäs, Markus Sjöblom, Femke Heindryckx   +5 more
wiley   +1 more source

AI-driven discovery of synergistic drug combinations against pancreatic cancer. [PDF]

Nat Commun
Pourmousa M, Jain S, Barnaeva E, Jin W, Hochuli J, Itkin Z, Maxfield T, Melo-Filho C, Thieme A, Wilson K, Klumpp-Thomas C, Michael S, Southall N, Jaakkola T, Muratov EN, Barzilay R, Tropsha A, Ferrer M, Zakharov AV.   +18 more
europepmc   +1 more source

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

FEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar, Francesco Michelangeli, Farhat Latif Khanim, Christopher Martin Bunce, William Eustace Basil Johnson   +4 more
wiley   +1 more source

Corrigendum: Network-based prediction of anti-cancer drug combinations

Frontiers in Pharmacology
Jue Jiang, Xuxu Wei, YuKang Lu, Simin Li, Xue Xu   +4 more
doaj   +1 more source

Antiepileptic Drug Combinations for Epilepsy: Mechanisms, Clinical Strategies, and Future Prospects. [PDF]

Int J Mol Sci
Li C, Wang X, Deng M, Luo Q, Yang C, Gu Z, Lin S, Luo Y, Chen L, Li Y, He B.   +10 more
europepmc   +1 more source

Time‐restricted feeding prior to Mycobacterium tuberculosis infection reduces tissue CD4+ T cells with limited impact on bacterial clearance

FEBS Open Bio, EarlyView.
Time‐restricted feeding (TRF) in mice increased liver fatty acid oxidation and decreased fatty acid biosynthesis. These alterations persisted when TRF was discontinued and the host was infected with Mycobacterium tuberculosis. Pre‐exposure to TRF did not alter tissue (lung and spleen) mycobacterial burden but significantly reduced CD3+ T cells in lungs
Ashish Gupta, Nidhi Yadav, Subhasmita Das, R. Rajendra Kumar Reddy, Nupur Sharma, Amol Ratnakar Suryawanshi, Jaswinder Singh Maras, Ranjan Kumar Nanda   +7 more
wiley   +1 more source

Statistical innovations in clinical trial design with a focus on drug combinations, factorials, and other multiple therapy issues. [PDF]

J Prev Alzheimers Dis
Berry DA.
europepmc   +1 more source

Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice

FEBS Open Bio, EarlyView.
In a murine model of myocardial ischemia and reperfusion (MI/R), the CD36 azapeptide ligand MPE‐298 reduces cardiac injury and transiently lowers left ventricular long‐chain fatty acids (LCFAs) accumulation 3 h after reperfusion, accompanied by a decrease of oxidative stress and inflammation‐associated genes' expression in the heart and adipose tissue.
Jade Gauvin, Naghme Radmannia, David N. Huynh, Liliane Ménard, Caroline Daneault, Maïté Veilleux, Ahsanullah Ahsanullah, André C. Carpentier, William D. Lubell, Matthieu Ruiz, Huy Ong, Sylvie Marleau, Simon‐Pierre Gravel   +12 more
wiley   +1 more source

Establishment of an <i>in vivo</i>-based assay using a silkworm infection model for phenotypic evaluation of antimicrobial drug combinations against <i>Mycobacterium abscessus</i>. [PDF]

Antimicrob Agents Chemother
Yagi A, Shinohara M, Minato Y, Uchida R.
europepmc   +1 more source